DHR earnings analysis — transcript, statement tables丹纳赫公司 (DHR) 财报解读 — 电话会、最新财务报表

Danaher Corporation Q2 2026 Earnings Follow-Up Analysis

Consensus Performance vs. Expectations

All results reflect continuing operations only, per the July 21, 2026 official earnings release. Adjusted diluted non-GAAP EPS came in at $1.94, beating consensus estimates by 5.4% (vs. $1.84 expected). Total revenue hit $6.3B, exceeding consensus by 2.6% (vs. $6.1B expected). GAAP diluted EPS was $1.23, per the financial statement snapshot.

Revenue and Profitability Quality

Quarterly revenue grew 5.3% YoY, with a 57.6% gross margin. Operating income totaled $1.1B, for an 18.0% operating margin, though operating income fell 16.1% YoY. EBIT and EBITDA both matched $1.1B, with an 18.0% margin. Net income was $870M, with a 13.9% net margin. Per the Q2 2026 earnings call transcript, adjusted operating margin was 27.1%, down 20 bps YoY, as lower respiratory testing revenue offset gains from non-respiratory volume growth and disciplined cost management. Core revenue excluding respiratory testing rose 4.5% YoY, accelerating 150 bps from Q1 2026.

Cash Conversion and Capital Position

Operating cash flow was $1.5B, capex totaled $269M, and free cash flow hit $1.3B. Year-to-date free cash flow to net income conversion ratio was 124%, signaling high-quality earnings. Ending cash balances were $4.3B, total debt $26.6B, and net debt $22.2B, per the financial statement snapshot.

Guidance Update

No specific numeric full-year guidance was parsed from available materials, but management stated in the earnings call transcript that they raised full-year adjusted EPS guidance earlier than expected following the early close of the Masimo acquisition, with no specific numerical targets disclosed.

GAAP vs. Non-GAAP Reconciliation

Both GAAP diluted EPS ($1.23) and adjusted diluted non-GAAP EPS ($1.94) were disclosed, with reconciliation details referenced on the company’s investor website per the call transcript.

Management Commentary

Per the July 21 earnings call transcript, management noted core growth accelerated on stronger commercial execution, innovation, and end-market recovery. Life sciences had its strongest quarter in years, diagnostics performed well, and bioprocessing order trends remained robust despite near-term project timing headwinds. High-growth markets saw core revenue up over 10% YoY, with mid-single-digit growth in China. Key product launches included the Biacore 8S SPR system, SCIEX novus V55 mass spectrometry platform, and CE-marked p-tau217 Alzheimer’s test. The Masimo acquisition closed early in June 2026 and is expected to be immediately accretive to adjusted EPS.

Unresolved Investor Questions

Detailed segment revenue breakdown, backlog/RPO data, deferred revenue, capex deployment plans, granular demand and pricing trends, and full 10-Q filing details are not available, as SEC filings have not been publicly disclosed as of this analysis.